首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1297778

全球分子診斷市場 - 2023-2030年

Global Molecular Diagnostics Market - 2023-2030

出版日期: 2023年06月15日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球分子診斷市場在2022年達到228億美元，預計到2030年將出現有利可圖的成長，達到357億美元。在預測期內（2023-2030），全球分子診斷市場預計將呈現5.9%的複合成長率。腫瘤學的日益盛行和各種應用的研究與開發的不斷發展，推動了分子診斷市場的需求趨勢。

分子診斷學，也被稱為基因變異的鑑定，其目標是使檢測、診斷、分類、預測結果和追踪治療反應更加容易。分子診斷學科是實驗室醫學、基因組學專業知識和技術成功互動的結果，特別是鑑於分子基因組技術的實質性進展。

所有這些因素都有助於識別和精確描述遺傳性疾病的遺傳基礎，這對提供準確的診斷至關重要。高通量技術，如全基因組關聯分析和下一代測序，提供了對疾病原因的關鍵洞察力。

分子診斷市場範圍包括腫瘤學、心血管疾病、傳染病和其他應用，這增加了分子診斷的市場佔有率。全球分子診斷市場正在擴大，因為包括診斷技術的不斷進步和各國即將進行的醫療審批等因素，也為分子診斷市場的成長創造了積極的前景。

市場動態

這些診斷產品提供的眾多優勢推動了分子診斷市場的成長。

這些分子診斷法提供了各種好處，例如特異性、敏感性、應用和周轉時間。擴增技術有利於提高方法學的靈敏度，定位只存在於不足濃度的重要目標分子。分子技術通過專注於感興趣的特定分子，減少假陽性測試結果的可能性。

與傳統的培養程序相比，分子方法通常提供更快的從接收到結果報告的周轉時間。分子技術的應用範圍更廣，包括識別和監測腫瘤標誌物、耐藥性、法醫學、基因測試和傳染性疾病。因此，不斷成長的新型產品的優勢推動了分子診斷市場的發展。

主要公司的技術進步不斷上升，為製造商創造了有利可圖的機會。

主要企業正在開發和推出各種技術先進的產品。目前在分子診斷技術和產品類型方面正在取得眾多的進步。

此外，2023年5月，A型噬菌體是導致結核病的細菌的天敵，它已經進化到可以躲避身體的免疫系統，現在正被用來在早期階段識別疾病。英國第一個噬菌體研究中心將於5月16日正式揭幕，並在創新英國Actiphage中強調，基於噬菌體的結核病分子診斷將在KTN上的英國噬菌體創新展示中亮相。

結核分枝桿菌（Mtb）是一種具有厚厚細胞壁的細菌，可以阻止其DNA的釋放，已被證明在檢測方面具有挑戰性，並且在培養中生長緩慢。 Actiphage利用一種噬菌體（一種只感染Mtb的病毒）搜索血液中的活Mtb細胞。根據位於萊斯特的NIHR呼吸系統生物醫學研究中心的研究，使用Actiphage在血液中發現的Mtb是活動性結核病的一個標誌；這代表了終結結核病鬥爭中的一個可能的進展。

虛假的測試結果將阻礙市場的成長。

依靠病原體的核酸而不是其表型的診斷方法受到一些問題的阻礙。一個重要的促成因素是大量的假陽性和假陰性結果。由於環境、實驗室、甚至準備反應混合物的工具中的DNA污染，一種疾病可能被錯誤地識別。與活細胞污染相比，DNA污染更難從表面或實驗室設備上清除，而活細胞污染很容易做到。

一個假陽性的結果可能來自於識別導致死亡的病原生物，而其全基因組的DNA仍然留在樣本中。由於在這些情況下，RNA不如DNA持久，基於RNA的程序如NASBA或RT-PCR提供了一個分子備份。因此，上述這些因素限制了分子診斷市場的成長。

COVID-19影響分析

由於COVID-19大流行和全球眾多國家的封鎖，所有行業的公司的財務健康都受到了影響。因此，在COVID-19公共衛生緊急情況期間，美國食品和藥物管理局（FDA）發布了指導方針，其中包括幫助贊助商和研究人員的一般注意事項，確保試驗參與者的安全，遵守良好的臨床實踐（GCP），並將試驗完整性的風險降到最低。

即時RT-PCR是識別COVID-19病毒最常用的實驗室技術之一。儘管許多國家已經採用即時RT-PCR技術來診斷其他疾病，如埃博拉和寨卡病毒，但許多國家仍然希望得到援助，將這種技術用於COVID-19病毒並擴大其國家診斷能力。

俄烏戰爭影響分析

估計俄烏衝突對全球分子診斷市場的影響不大，因為這一地區的主要市場參與者數量不多。然而，在預測期內，原料進出口的影響預計對全球分子診斷市場的成長影響不大。

Market Overview

The Global Molecular Diagnostics Market reached US$ 22.8 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 35.7 billion by 2030. The Global Molecular Diagnostics Market is expected to exhibit a CAGR of 5.9% during the forecast period (2023-2030). The increasing prevalence of oncology and the growing research and development for various applications drive demand for molecular diagnostics market trends.

The goal of molecular diagnostics, also known as the identification of genetic variations, is to make it easier to detect, diagnose, classify, predict outcomes, and track therapeutic response. The discipline of molecular diagnostics results from the successful interaction of laboratory medicine, genomics expertise, and technology, particularly in light of substantial advancements in molecular genomic technologies.

All these elements help identify and precisely characterize the genetic underpinnings of hereditary disorders, which is essential for providing an accurate diagnosis. High-throughput techniques, such as genome-wide association analyses and next-generation sequencing, offer crucial insights into disease causes.

The Molecular Diagnostics Market scope comprises applications as oncology, cardiovascular disorders, infectious diseases and others, which has increased the molecular diagnostics market share. The global market for molecular diagnostics is expanding as a result of factors including the increasing advances in diagnostics technology and their upcoming medical approvals across countries are also creating a positive outlook for the molecular diagnostics market growth.

Market Dynamics

Numerous Advantages Provided by these Diagnostic Products drive the growth of the molecular diagnostics market.

These molecular diagnostics provide various benefits for instance, specificity, sensitivity, applications and turnaround time. Amplification techniques are beneficial for raising a methodology's sensitivity and locating target molecules of significance that only exist at deficient concentrations. Molecular techniques reduce the likelihood of false positive test findings by focusing on the particular molecule of interest.

Molecular approaches typically offer faster turnaround times from receiving to result reporting than traditional culture procedures. Molecular techniques have a wider range of applications, including in identifying and monitoring tumor markers, medication resistance, forensics, genetic testing, and infectious disorders. Hence, the growing novel products' advantages drives the molecular diagnostics market.

Rising Technological Advancements by Key Companies create lucrative opportunities for manufacturers.

A variety of technologically advanced products are being developed and launched by the major players. Numerous advancements are currently being made in molecular diagnostic technology and product type.

Furthermore, in May 2023, A phage, a natural enemy of the bacteria that causes tuberculosis and which has evolved to elude the body's immune system, is now being used to identify the illness at an early stage. The first Center for Phage Research in the UK will be formally unveiled on May 16 and highlighted in the Innovate UK Actiphage, a molecular diagnostic for tuberculosis based on phages will be featured in the UK Phage Innovation Showcase on KTN.

Mycobacterium tuberculosis (Mtb), a bacterium with a thick cell wall that blocks the release of its DNA, has proven challenging to detect and is slow to grow in culture. Actiphage searches the blood for live Mtb cells using a phage, a virus that only infects Mtb. Mtb discovered in the blood using Actiphage is a sign of active TB disease, according to research from the NIHR Respiratory Biomedical Research Centre in Leicester; this represents a possible advance in the fight to End TB.

False Test Outcomes will hamper the growth of the market.

Diagnostic assays that depend on the nucleic acids of the pathogen instead of on its phenotype are hampered by a few issues. A significant contributing factor is the high number of false positive and false negative outcomes. A disease may be mistakenly identified due to DNA contamination in the environment, the lab, and even the tools for preparing the reaction mix. DNA contamination is more difficult to remove from surfaces or lab equipment than living cell contamination, which can be easily done.

A false positive outcome could come from identifying pathogenic organisms that cause death and whose genome-wide DNA remains in the sample. Since RNA is less durable than DNA in these circumstances, RNA-based procedures like NASBA or RT-PCR provide a molecular backup. Hence these above-mentioned factors are limiting the molecular diagnostics market's growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations worldwide. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Real-time RT-PCR is one of the most used laboratory techniques to identify the COVID-19 virus. Although many nations have employed real-time RT-PCR to diagnose other illnesses like the Ebola and Zika viruses, many still want assistance in adapting this technique for the COVID-19 virus and expanding their national diagnostic capacities.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global molecular diagnostics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global molecular diagnostics market growth over the forecast period.

Segment Analysis

The Global Molecular Diagnostics Market is segmented based on product type, technology, application, end-user and region.

Instruments from the product type segment account for 37.3% of the market share owing to rising novel product launches.

Sample-to-answer instruments are designed to accept single-use cartridges with integrated Reagents and Kits that allow the detection of single or multiple targets in a patient's sample. The ideal option for mobile laboratories are diagnostic devices utilizing hermetically sealed cartridges that can withstand travel and extended storage in various climatic conditions without requiring a cold chain.

Various instruments are being launched with advanced technology. For instance, molecular biology, genomics, proteomics, and pharmacology techniques can all be accommodated by the Liquid Handling workstation known as EXTRAlab. It is distinguished by its great degree of adaptability. The workstation enables the creation of a fully automated lab to carry out sample preparation, dilution, and dispensing.

The modular design allows for simple reconfiguration to fit the customer's unique needs. For example, the liquid handling system can be modified to handle a variety of volumes and can have additional devices integrated on the basic platform.

Geographical Analysis

Due to major players' strong presence and increasing technological advancements, North America accounted for approximately 37.1% of the market share.

Manufacturers have chances to expand their operations in this region because of the rising demand for molecular diagnostics for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of molecular diagnostics, increasing demand.

North America has a large number of producers and suppliers. As a result of the swift economic development of the area, industrial production has increased, fueling the demand of molecular diagnostics.

Rising new product types or applications will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various diagnostic approaches for cancer or other disorders, leading to expanding the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the molecular diagnostics market include: Illumina, Inc., F Hoffmann-la Roche Ltd, Abbott, Bio-Rad Laboratories, Inc., BD, Hologic Inc., Myriad Genetics, Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc. and Danaher among others.

Why Purchase the Report?

To visualize the Global Molecular Diagnostics Market segmentation based on product type, technology, application, end-user and region, and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous molecular diagnostics market-level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Molecular Diagnostics Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Numerous Advantages Provided by these Diagnostic Products
  - 4.1.1.2. Increasing Demand for Point-of-care Diagnostics
- 4.1.2. Restraints
  - 4.1.2.1. False Test Outcomes
- 4.1.3. Opportunity
  - 4.1.3.1. The Rising Technological Advancements by Key Companies
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Reagents and Kits *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Instruments
7.4. Software & Services

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. PCR (Polymerase Chain Reaction) *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Fluorescence In Situ Hybridization
8.4. Next-Generation Sequencing
8.5. Isothermal Nucleic Acid Amplification Technology (INAAT)
8.6. Others

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Oncology *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cardiovascular Diseases
9.4. Infectious Diseases
9.5. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Diagnostic Laboratories *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospitals
10.4. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. The U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. The U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan

Australia

11.5.7.4. Rest of Asia-Pacific

11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. F. Hoffmann-la Roche Ltd *
- 13.1.1. Company Overview
- 13.1.2. Product Type Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Illumina, Inc.
13.3. Abbott
13.4. BD
13.5. Bio-Rad Laboratories, Inc.
13.6. Hologic, Inc.
13.7. Agilent Technologies Inc.
13.8. Myriad Genetics, Inc.
13.9. Thermo Fisher Scientific Inc.
13.10. Danaher

LIST NOT EXHAUSTIVE